PAB Stock Overview
Develops and commercializes antibody technologies for the treatment of cancer in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Patrys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0045 |
| 52 Week High | AU$0.01 |
| 52 Week Low | AU$0.003 |
| Beta | 0.56 |
| 11 Month Change | 50.00% |
| 3 Month Change | -25.00% |
| 1 Year Change | -55.00% |
| 33 Year Change | -88.46% |
| 5 Year Change | -77.50% |
| Change since IPO | -99.29% |
Recent News & Updates
Recent updates
Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year
Nov 08
Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?
Mar 24Here's Why Some Shareholders May Not Be Too Generous With Patrys Limited's (ASX:PAB) CEO Compensation This Year
Nov 09Will Patrys (ASX:PAB) Spend Its Cash Wisely?
Sep 01Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?
May 11We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate
Sep 28We're Hopeful That Patrys (ASX:PAB) Will Use Its Cash Wisely
Jun 15Companies Like Patrys (ASX:PAB) Are In A Position To Invest In Growth
Mar 01What Can We Make Of Patrys' (ASX:PAB) CEO Compensation?
Jan 07
Shareholder Returns
| PAB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 50.0% | 1.4% | 1.5% |
| 1Y | -55.0% | 16.9% | 17.3% |
Return vs Industry: PAB underperformed the Australian Biotechs industry which returned 16.9% over the past year.
Return vs Market: PAB underperformed the Australian Market which returned 17.3% over the past year.
Price Volatility
| PAB volatility | |
|---|---|
| PAB Average Weekly Movement | 33.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PAB's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: PAB's weekly volatility has increased from 22% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | James Campbell | www.patrys.com |
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs. In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications.
Patrys Limited Fundamentals Summary
| PAB fundamental statistics | |
|---|---|
| Market cap | AU$9.26m |
| Earnings (TTM) | -AU$3.54m |
| Revenue (TTM) | AU$1.39m |
6.6x
P/S Ratio-2.6x
P/E RatioIs PAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAB income statement (TTM) | |
|---|---|
| Revenue | AU$1.39m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.39m |
| Other Expenses | AU$4.93m |
| Earnings | -AU$3.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0017 |
| Gross Margin | 100.00% |
| Net Profit Margin | -253.85% |
| Debt/Equity Ratio | 0% |
How did PAB perform over the long term?
See historical performance and comparison